Solid Biosciences (SLDB) Amortizatization of Intangibles (2017 - 2026)
Solid Biosciences (SLDB) posted Amortizatization of Intangibles of $619000.0 for Q1 2026, down 17.14% sequentially from $747000.0 in Q4 2025, and up 98.4% YoY from $312000.0 in Q1 2025.
Powered by 
Analysis
Solid Biosciences (SLDB) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Solid Biosciences has reported Amortizatization of Intangibles for 10 years, with the latest figure at $619000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 98.4% year-over-year to $619000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 35.17% YoY) and the FY2025 annual result came in at $1.9 million, down 47.83% from the prior year.
- Amortizatization of Intangibles fell to $619000.0 in Q1 2026 per SLDB's latest filing, from $747000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.2 million in Q3 2024 and troughed at -$371000.0 in Q1 2022.
- A 5-year average of $485882.4 and a median of $488000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles soared 5688.24% in 2023, then sank 72.93% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $276000.0 in 2022, then soared by 317.03% to $1.2 million in 2023, then sank by 30.23% to $803000.0 in 2024, then slipped by 6.97% to $747000.0 in 2025, then retreated by 17.14% to $619000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $619000.0, $747000.0, and $327000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | 1.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Mn |
| Mar 31, 2026 | 619,000.00 |
| Dec 31, 2025 | 747,000.00 |
| Sep 30, 2025 | 327,000.00 |
| Jun 30, 2025 | 488,000.00 |
| Mar 31, 2025 | 312,000.00 |
| Dec 31, 2024 | 803,000.00 |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 540,000.00 |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 984,000.00 |
| Jun 30, 2023 | 58,000.00 |
| Mar 31, 2023 | 215,000.00 |
| Dec 31, 2022 | 276,000.00 |
| Sep 30, 2022 | 17,000.00 |
| Jun 30, 2022 | -155,000.00 |
| Mar 31, 2022 | -371,000.00 |
| Dec 31, 2021 | -582,000.00 |
| Sep 30, 2021 | -528,000.00 |